SOPHiA GENETICS Raises 2025 Outlook on Accelerating Growth, Strategic Wins
March 3, 2026 — 8:00 AM ET
In a clear sign of building momentum, SOPHiA GENETICS (NASDAQ: SOPH) today reported robust third-quarter results and raised its full-year revenue guidance, underscoring a successful strategic pivot and growing demand for its decentralized data analytics platform in precision medicine.
The company posted a 23% year-over-year revenue increase to $19.5 million, marking the third straight quarter of accelerating growth. This performance has prompted management to raise its 2025 revenue outlook to a range of $75 million to $77 million, up from the previous $72 million to $76 million forecast.
"The business momentum we've highlighted for several quarters is now translating directly into our financial results," said CEO Jurgi Camblong during the earnings call. "We are seeing strength across new customer acquisitions, expansion within existing accounts, and key strategic applications like our MSK Access liquid biopsy solution."
Strategic Drivers Fuel Growth
The quarter's success was attributed to three core growth drivers. First, the company signed 31 new customers in Q3, bringing the 2025 total to 94—already surpassing the 92 customers signed in all of 2024. Notable new clients include Geisinger Health System, Baylor Scott & White Health, and Thermo Fisher Life Labs.
Second, expansion within the existing customer base was "exceptionally strong," according to Camblong. Top-tier institutions like Paris's Gustave Roussy and Australia's New South Wales Pathology added new applications, demonstrating the platform's "land-and-expand" model in action.
Third, the MSK Access liquid biopsy platform continues to gain traction, now serving 60 customers worldwide. The company also announced strategic partnerships with Myriad Genetics in the U.S. and ADAM Innovations in Japan to develop MSK Access into a regulated companion diagnostic, aiming to create a first-of-its-kind global hybrid CDx assay for biopharma.
Financial Discipline and Innovation
Despite a 40% year-over-year increase in data processed, SOPHiA GENETICS maintained an adjusted gross margin of 73.1%. CFO George Cardoza highlighted the company's ability to grow revenue without a substantial increase in headcount or operating expenses, demonstrating "natural operating leverage."
The company also unveiled a breakthrough research tool at the recent ESMO conference: SOPHiA DDM Digital Twins. This AI-powered technology creates dynamic virtual models of individual patients to simulate treatment outcomes, representing a significant step beyond genomic analysis alone.
Market Analysts Weigh In
"The raised guidance and consecutive acceleration are undeniable positives," said Dr. Anya Sharma, a biotech equity analyst at Horizon Capital. "The partnerships with Myriad and ADAM for companion diagnostics could open a massive, high-margin revenue stream. However, the path to EBITDA breakeven by 2026 remains challenging, and the legal overhang from Guardant Health's patent suit is a non-trivial risk."
Michael Torres, a portfolio manager focused on healthcare innovation, offered a more bullish take: "This is a textbook execution story. They've navigated biopharma headwinds, are winning larger deals, and are at the forefront of two megatrends: decentralized testing and AI in oncology. The digital twins announcement isn't just R&D—it's a glimpse into a future where their platform becomes indispensable for treatment decisions."
Lisa Chen, a former lab director and now independent industry blogger, reacted sharply: "Let's not get carried away. Signing 31 'customers' sounds great, but how many are pilot projects that will never scale? The 'decentralized' narrative is convenient, but the real money in diagnostics has always been in centralized, high-volume labs. Their partnership model for CDx feels like an admission they can't crack the regulatory market alone. I'll believe the hype when their bottom line turns black."
Robert Flynn, a healthcare IT consultant, provided a balanced view: "The data speaks for itself—accelerating growth, record bookings, and impressive cost control. The strategic vision to connect decentralized labs into a global network for biopharma R&D is compelling. The key watchpoint is implementation velocity; they need to convert that record backlog into recurring revenue faster to sustain this momentum into 2026."
Looking ahead, management expressed confidence in the company's trajectory, citing a strong pipeline, larger average contract values, and a recovering biopharma sector. They reiterated their goal of approaching adjusted EBITDA breakeven by 2026.